雍禾醫療公佈配售結果，你中籤了嗎？快來曬單吧！
IPO Pricing | Yonghe Medical received 160.06 times oversubscription, with a price of HK$15.8 per share.
Futu news on December 10 announced that this Friday$YONGHE MEDICAL (02279.HK)$announced that the company issued 94.424 million shares priced at HK$15.8 per share, in units of 500 shares, expected to be listed on December 13.
During the public offering stage, YongHe Medical received about 160.06 times oversubscription. The final number of shares allocated to the public offering of shares is 47.212 million shares, accounting for 50% of the total number of shares offered (before any exercise of the oversubscription rights). A total of 81,126 valid applications were received, with a 15% allotment rate for first-time applicants, subscribing for 16 lots with stability in one lot.
In addition, the international offering shares were oversubscribed by about 8.39 times. The final number of shares allocated to the international offering shares is 47.212 million shares, equivalent to 50% of the total number of shares offered (before any exercise of oversubscription rights). Futu news organizes the relevant data as shown in the table below:
The net income of approximately 1.357 billion Hong Kong dollars will be used for the following purposes: about 42.1% will be used to expand and upgrade the company's existing hair transplant medical institutions in China; about 17.5% will be used to provide funds for product and service innovation projects; about 9.7% will be invested in research and development, and to enhance its service system with cutting-edge technology; about 23.4% will be used to integrate industry resources in China to enhance brand awareness; about 1.6% will be used to settle the unpaid balance of the acquisition cost of the prominent hair transplant affiliated with Xin Siyu which the company acquired in May 2021; about 5.7% will be used for operating funds and general corporate purposes.
YongHe Medical is a leading medical group in China specializing in providing hair medical services, offering one-stop hair medical services, including hair transplant medical services, medical care and maintenance, routine care, and other ancillary services.
According to Frost & Sullivan data, based on the total revenue generated from relevant services in 2020, the company isThe largest enterprise in the China hair transplant medical services and medical care market, with market shares of 10.5% and 4.3% respectively.
Among all hair medical service providers in China, based on the number of registered doctors at the end of 2020, the number of operating medical institutions at the end of 2020, and the number of hair transplant patients in 2020,Yonghe Medical ranks first.
As of the latest feasible date, Yonghe Medical operates 53 medical institutions in 52 cities nationwide, making it the largest and most widely covered chain of hair transplant medical institutions in China.
In terms of financial data, partly driven by the rapid expansion of its medical institution network, the company achieved significant growth in its financial performance during the past reporting periods.
From 2018 to 2020, Yonghe Medical achieved revenues of RMB 0.934 billion, 1.224 billion, and 1.638 billion, with a compound annual growth rate of 32.4%; during the same period, net income recorded RMB 53.5 million, 35.624 million, and 163 million, with a compound annual growth rate of 74.7%.
In the first half of 2021, the company recorded a total revenue of 1.053 billion yuan, a year-on-year increase of 75.1%; net profit for the same period was 40.441 million yuan, a decrease from the same period in 2020.
In recent years, influenced by a combination of factors such as the continuous increase in per capita disposable income of Chinese residents, the enhancement of self-awareness of appearance, and the progress of hair transplant technology, the Chinese hair transplant service market has rapidly grown from 5.8 billion yuan in 2016 to 13.4 billion yuan in 2020, with a compound annual growth rate of 23.4%.
However, compared to the actual number of people experiencing hair loss in China, the number of people receiving hair transplant medical services is relatively small. Calculated by dividing the number of hair transplant recipients by the number of hair loss patients, the hair transplant penetration rate in China in 2020 was only about 0.2%, indicating a huge unmet market demand and significant growth potential.It is estimated that the size of the Chinese hair transplant service market will reach 75.6 billion yuan by 2030.
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Comments (14)
to post a comment
49
104